Dietary glycotoxins induce RAGE and VEGF up-regulation in the retina of normal rats

Experimental Eye Research

Volumn 137, Issue , 2015, Pages 1-10

  Kandarakis, Stylianos A ^a   Piperi, Christina ^a   Moschonas, Dimitrios P ^a   Korkolopoulou, Penelope ^a   Papalois, Apostolos ^b   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ELPEN Pharmaceuticals   (Greece)

Author keywords

Advanced glycation end products; Glycotoxins; Ocular tissues; RAGE; VEGF A

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; FRUCTOSAMINE; GLYCOTOXIN; TOXIN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; FRUCTOSAMINE BLOOD LEVEL; GROUPS BY AGE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INSULIN BLOOD LEVEL; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RETINA; RETINA GANGLION CELL; UPREGULATION; ANIMAL; BIOSYNTHESIS; CYTOLOGY; DIET SUPPLEMENTATION; METABOLISM; WISTAR RAT;

ANIMALS; DIETARY SUPPLEMENTS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; IMMUNOHISTOCHEMISTRY; RATS; RATS, WISTAR; RETINAL PIGMENT EPITHELIUM; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84931265286     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2015.05.017     Document Type: Article

References (52)

1. Adamis A.P., Shima D.T., Yeo K.T., Yeo T.K., Brown L.F., Berse B., D'Amore P.A., Folkman J. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem. Biophys. Res. Commun. 1993, 193:631-638.
2. Basta G., Schmidt A.M., De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 2004, 63:582-592.
3. Bok D. The retinal pigment epithelium: a versatile partner in vision. J.Cell Sci. 1993, 17:189-195.
4. Boucher S., Varin F., Theoret Y., Du Souich P., Caille G. High-performance liquid chromatographic method for the determination of diltiazem and two of its metabolites in human plasma: application to a new sustained release formulation. J.Pharm. Biomed. Anal. 1989, 7:1925-1930.
5. Cai W., He J.C., Zhu L., Chen X., Zheng F., Striker G.E., Vlassara H. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am. J. Pathol. 2008, 173:327-336.
6. Chatzigeorgiou A., Kandaraki E., Piperi C., Livadas S., Papavassiliou A.G., Koutsilieris M., Papalois A., Diamanti-Kandarakis E. Dietary glycotoxins affect scavenger receptor expression and the hormonal profile of female rats. J.Endocrinol. 2013, 218:331-337.
7. Chavakis T., Bierhaus A., Nawroth P.P. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect. 2004, 6:1219-1225.
8. Chiu C.J., Chang M.L., Zhang F.F., Li T., Gensler G., Schleicher M., Taylor A. The relationship of major American dietary patterns to age-related macular degeneration. Am. J. Ophthalmol. 2014, 158:118-127. e1.
9. Clements R.S., Robison W.G., Cohen M.P. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice. J.Diabetes Complicat. 1998, 12:28-33.
10. de Assis A.M., Rieger D.K., Longoni A., Battu C., Raymundi S., da Rocha R.F., Andreazza A.C., Farina M., Rotta L.N., Gottfried C., Gonçalves C.A., Moreira J.C., Perry M.L. High fat and highly thermolyzed fat diets promote insulin resistance and increase DNA damage in rats. Exp. Biol. Med. (Maywood) 2009, 234:1296-1304.
11. Diamanti-Kandarakis E., Piperi C., Kalofoutis A., Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf) 2005, 62:37-43.
12. Diamanti-Kandarakis E., Piperi C., Korkolopoulou P., Kandaraki E., Levidou G., Papalois A., Patsouris E., Papavassiliou A.G. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J.Mol. Med. Berl. 2007, 85:1413-1420.
13. Diamanti-Kandarakis E., Piperi C., Patsouris E., Korkolopoulou P., Panidis D., Pawelczyk L., Papavassiliou A.G., Duleba A.J. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem. Cell Biol. 2007, 127:581-589.
14. Glenn J.V., Mahaffy H., Wu K., Smith G., Nagai R., Simpson D.A., Boulton M.E., Stitt A.W. Advanced glycation end product (AGE) accumulation on Bruch's membrane: links to age-related RPE dysfunction. Invest. Ophthalmol. Vis. Sci. 2009, 50:441-451.
15. Goh S.Y., Cooper M.E. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J.Clin. Endocrinol. Metab. 2008, 93:1143-1152.
16. Hammes H.P., Alt A., Niwa T., Clausen J.T., Bretzel R.G., Brownlee M., Schleicher E.D. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999, 42:728-736.
17. Hirata C., Nakano K., Nakamura N., Kitagawa Y., Shigeta H., Hasegawa G., Ogata M., Ikeda T., Sawa H., Nakamura K., Ienaga K., Obayashi H., Kondo M. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. Biochem. Biophys. Res. Commun. 1997, 236:712-715.
18. Hong T., Tan A.G., Mitchell P., Wang J.J. Areview and meta-analysis of the association between C-reactive protein and age-related macular degeneration. Surv. Ophthalmol. 2011, 56:184-194.
19. Ibrahim A.S., El-Remessy A.B., Matragoon S., Zhang W., Patel Y., Khan S., Al-Gayyar M.M., El-Shishtawy M.M., Liou G.I. Retinal microglial activation and inflammation induced by amadori-glycated albumin in a rat model of diabetes. Diabetes 2011, 60:1122-1133.
20. Kandaraki E., Chatzigeorgiou A., Piperi C., Palioura E., Palimeri S., Korkolopoulou P., Koutsilieris M., Papavassiliou A.G. Reduced ovarian glyoxalase-I activity by dietary glycotoxins and androgen excess: a causative link to polycystic ovarian syndrome. Mol. Med. 2012, 18:1183-1189.
21. Kandarakis S.A., Piperi C., Topouzis F., Papavassiliou A.G. Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases. Prog. Retin. Eye Res. 2014, 42:85-102.
22. Kankova K. Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?. Proc. Nutr. Soc. 2008, 67:60-74.
23. Kawashima M., Ozawa Y., Shinmura K., Inaba T., Nakamura S., Kawakita T., Watanabe M., Tsubota K. Calorie restriction (CR) and CR mimetics for the prevention and treatment of age-related eye disorders. Exp. Gerontol. 2013, 48:1096-1100.
24. Lee S.G., Lee C.G., Yun I.H., Hur D.Y., Yang J.W., Kim H.W. Effect of lipoic acid on expression of angiogenic factors in diabetic rat retina. Clin. Exp. Ophthalmol. 2012, 40:e47-57.
25. Li L., Renier G. Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression. Metabolism 2006, 55:1516-1523.
26. Li J., Hou F.-, Guo Z.-, Shan Y.-, Zhang X., Liu Z.- Advanced glycation end products upregulate C-reactive protein synthesis by human hepatocytes through stimulation of monocyte IL-6 and IL-1 beta production. Scand. J. Immunol. 2007, 66:555-562.
27. Lu M., Kuroki M., Amano S., Tolentino M., Keough K., Kim I., Bucala R., Adamis A.P. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J.Clin. Invest 1998, 101:1219-1224.
28. Ma K., Xu Y., Wang C., Li N., Li K., Zhang Y., Li X., Yang Q., Zhang H., Zhu X., Bai H., Ben J., Ding Q., Li K., Jiang Q., Xu Y., Chen Q. Across talk between class a scavenger receptor and receptor for advanced glycation end-products contributes to diabetic retinopathy. Am. J. Physiol. Endocrinol. Metab. 2014, 307:E1153-E1165.
29. Ma W., Lee S.E., Guo J., Qu W., Hudson B.I., Schmidt A.M., Barile G.R. RAGE ligand upregulation of VEGF secretion in ARPE-19 cells. Invest. Ophthalmol. Vis. Sci. 2007, 48:1355-1361.
30. Nagaraj R.H., Linetsky M., Stitt A.W. The pathogenic role of Maillard reaction in the aging eye. Amino Acids 2012, 42:1205-1220.
31. Pemp B., Polska E., Karl K., Lasta M., Minichmayr A., Garhofer G., Wolzt M., Schmetterer L. Effects of antioxidants (AREDS medication) on ocular blood flow and endothelial function in an endotoxin-induced model of oxidative stress in humans. Invest. Ophthalmol. Vis. Sci. 2010, 51:2-6.
32. Puddu A., Sanguineti R., Durante A., Nicolò M., Viviani G.L. Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization. Mol. Vis. 2012, 18:2509-2517.
33. Rodriguez J., Sanchez R., Munoz B., West S.K., Broman A., Snyder R.W., Klein R., Quigley H. Causes of blindness and visual impairment in a population-based sample of U.S. Hispanics. Ophthalmol 2002, 109:737-743.
34. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J.Clin. Invest 2001, 108:949-955.
35. Schmidl D., Garhofer G., Schmetterer L. Nutritional supplements in age-related macular degeneration. Acta Ophthalmol. 2015, 93:105-121.
36. Seddon J.M., Gensler G., Milton R.C., Klein M.L., Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA 2004, 291:704-710.
37. Semba R.D., Nicklett E.J., Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype?. J.Gerontol. A Biol. Sci. Med. Sci. 2010, 65:963-975.
38. Semba R.D., Beck J., Sun K., Egan J.M., Carlson O.D., Varadhan R., Ferrucci L. Relationship of a dominant advanced glycation end product, serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: the Baltimore Longitudinal Study of Aging. J.Nutr. Health Aging 2010, 14:507-513.
39. Schalkwijk C.G., Ligtvoet N., Twaalfhoven H., Jager A., Blaauwgeers H.G., Schlingemann R.O., Tarnow L., Parving H.H., Stehouwer C.D., van Hinsbergh V.W. Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes 1999, 48:2446-2453.
40. Schalkwijk C.G., Miyata T. Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics. Amino Acids 2012, 42:1193-1204.
41. Shimizu F., Sano Y., Haruki H., Kanda T. Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood-nerve barrier by stimulating the release of TGF-beta and vascular endothelial growth factor (VEGF) by pericytes. Diabetologia 2011, 54:1517-1526.
42. Shimizu F., Sano Y., Tominaga O., Maeda T., Abe M.A., Kanda T. Advanced glycation end-products disrupt the blood-brain barrier by stimulating the release of transforming growth factor-beta by pericytes and vascular endothelial growth factor and matrix metalloproteinase-2 by endothelial cells invitro. Neurobiol. Aging 2013, 34:1902-1912.
43. Stitt A.W., Curtis T.M. Advanced glycation and retinal pathology during diabetes. Pharmacol. Rep. 2005, 57:156-168.
44. Strauss O. The retinal pigment epithelium in visual function. Physiol. Rev. 2005, 85:845-881.
45. Treins C., Giorgetti-Peraldi S., Murdaca J., Van Obberghen E. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J.Biol. Chem. 2001, 276:43836-43841.
46. Uribarri J., Cai W., Peppa M., Goodman S., Ferrucci L., Striker G., Vlassara H. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J.Gerontol. A Biol. Sci. Med. Sci. 2007, 62:427-433.
47. Yamagishi S., Abe R., Jinnouchi Y., Matsui T., Imaizumi T., Inoue H. Pigment epithelium-derived factor inhibits vascular endothelial growth factor-induced vascular hyperpermeability both invitro and invivo. J.Int. Med. Res. 2007, 35:896-899.
48. Yoshida T., Yamagishi S., Nakamura K., Matsui T., Imaizumi T., Takeuchi M., Ueno T., Sata M. Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. FEBS Lett. 2006, 580:2788-2796.
49. Yoshida T., Yamagishi S., Nakamura K., Matsui T., Imaizumi T., Takeuchi M., Koga H., Ueno T., Sata M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 2006, 49:3094-3099.
50. Zhong Y., Li S.H., Liu S.M., Szmitko P.E., He X.Q., Fedak P.W., Verma S. C-Reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension 2006, 48:504-511.
51. Zicari A.M., Zicari A., Nebbioso M., Mari E., Celani C., Lollobrigida V., Cesoni Marcelli A., Occasi F., Duse M. High-mobility group box-1 (HMGB-1) and serum soluble receptor for advanced glycation end products (sRAGE) in children affected by vernal keratoconjunctivitis. Pediatr. Allergy Immunol. 2014, 25:57-63.
52. Zong H., Ward M., Stitt A.W. AGEs, RAGE, and diabetic retinopathy. Curr. Diab. Rep. 2011, 11:244-252.